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Abstract.  
 
Bacterial expression of β-lactamases is the most widespread resistance mechanism to β -lactam 
antibiotics. There is a pressing need for novel, non-β-lactam inhibitors of these enzymes.  
Our lead, compound 1, is chemically dissimilar to β -lactams and is a noncovalent, competitive 
inhibitor of the enzyme. However, at 26 µM its activity is modest (Figure 1).  
Using the X-ray structure of the AmpC/1 complex as a template, 14 analogues were designed and 
synthesized. Among these, compound 10, had a Ki of 1 µM, 26-fold better than the lead.  
The structures of AmpC in complex with compound 10 and an analogue, compound 11, were 
determined by X-ray crystallography to 1.97 and 1.96 Å, respectively.  
Compound 10 was active in cell culture, reversing resistance to the third generation cephalosporin 
ceftazidime in bacterial pathogens expressing AmpC. In contrast to β-lactam-based inhibitors 
compound 10 did not up-regulate β-lactamase expression in cell culture but simply inhibited the 
enzyme expressed by the resistant bacteria. Its escape from this resistance mechanism derives 
from its dissimilarity to β -lactam antibiotics. 
Introduction.  
β-lactamases catalyze the hydrolysis of β-lactam antibiotics and are the most widespread 
resistance mechanism to these drugs (Figure 2). β-lactam based inhibitors and “β-lactamase 
resistant” β-lactams have been introduced to overcome this problem, but they resemble the 
substrates, and bacteria have rapidly become resistant to these anti-resistance drugs. 
Among several bacterial resistance mechanisms, the most serious adaptations is represented by β-
lactamases themselves. Mutant variants β-lactamase have arisen that can evade β-lactam-based β-
lactamase inhibitors (i.e. clavulanic acid). Enzymes that are naturally resistant to current β-
lactamase inhibitors, including the class C β-Lactamases such as AmpC, have become 
increasingly prominent.  
There is a pressing need for novel β-lactamase inhibitors. Such inhibitors would not be 
hydrolyzable by β-Lactamases and would not be recognized by the suite of bacterial resistance 
mechanisms mobilized against β-lactam-based β-lactamase inhibitors.  
Figure 3. A 2[Fo] – [Fc] electron density 
maps (blue) of the refined model of AmpC in 
complex with compound 10 contoured at 1σ. 
The simulated-annealing omit electron density 
maps for the inhibitors, is contoured at 3σ.  
Co-crystals of AmpC with 10 were grown 
from 1.8M KPi, pH 8.7 in hanging drops. 
Diffraction data were collected at the Advance 
Light Source (ALS, Lawrence Berkeley 
Laboratory, CA). Space group: C2. Cell 
constants: a=117.75Å; b=76.77Å c=97.90Å 
β=116.63°. Unique reflections=55,165. Total 
reflections=105,106. Rmerge=9.1% (25.8%). 
Completeness: 93.7% (94.6%). R=16.84%, 
Rfree=21.5%. 
Figure 4. Active site of AmpC β-lactamase in 
complex with compound 10. Dashed yellow 
lines represent key interactions. Red spheres 
represent water molecules.  
Microbiology.  
 
To investigate the potential of these compounds to reverse antibiotic resistance compounds 10 
was tested in bacterial cell culture for synergy with the third generation cephalosporin 
ceftazidime (CAZ) against pathogenic bacteria from clinical isolates.  
Compound 10 increased bacterial susceptibility to CAZ, improving its MIC values by 4- to 8-
fold. Compound 10 synergized the activity of CAZ and the penicillin piperacillin (PIP) in disk 
diffusion assays but did not up-regulate its expression in cell culture, as do classic β-lactam-based 
inhibitors clavulanate and cefoxitin (Figure 5). 
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Figure 2. β-lactam hydrolysis by serine β-lactamases  
Compound 1: a novel inhibitor 
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Figure 1. Confronting β-lactam and novel inhibitor of AmpC  
Design and Synthesis.  
 
We recently reported the discovery through virtual screening of a novel, non covalent inhibitor of 
AmpC, compound 1 (Figure 1). Though novel, the inhibitor was weak (Ki 26 µM) and its activity 
in vivo was poor. The crystallographic complex of AmpC-1 revealed that compound 1 is highly 
complementary to the enzyme in the region where it bind, but leaves part of the binding site open. 
We wished to investigate which groups in the lead inhibitor 1 were critical for binding, and should 
be maintained, and where we could improve affinity through chemical elaboration.  
In the design of 14 new derivatives, while exploring the structure-activity relationship pf the series, 
we considered both structural complementarity and bioavailability. 
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Table 1. Ki values of thiophene-carboxy derivatives vs AmpC 
Enzymology and Binding Affinity.  
 
Derivates that replaced the thiophene carboxylate with a methyl ester substantially reduced affinity, 
consistent with the importance of the ion-dipole interactions made by this carboxylate (e.g., 
compound 1A, Table 1). Similarly, inverting the order of the sulfonyl-amino group reduced affinity 
10-20-fold (compare compounds 1 and 2 or 11 and 14, Table 1), and replacing the sulfonamide with 
an amide reduced affinity 8-fold, consistent with the importance of the hydrogen bond between this 
group and Asn152 observed crystallographically.  
  
In an attempt to increase the affinity of compound 1, we considered derivates that improved either 
the apolar or polar complementarity in the distal chloro-phenyl ring of the inhibitor. This 
functionality is located in a more open region of the active site, flanked by the conserved Tyr221 on 
the “floor” of the active site, bulk solvent at the “top” of the inhibitor, and polar and apolar residues 
(Arg204, Gly320, Thr319, and Val211) to its side. More polar derivates, such as carboxylate and 
hydroxyl groups, improved affinity more substantially, up to 26-fold in compounds 7-10 (Table 1). 
Figure 5. 	

The effects on up-regulation of a class C β-lactamase in E. cloacae by β-lactamase inhibitors:	

A. The β-lactam based inhibitor clavulanate (center), with piperacillin (PIP) and ceftazidime (CAZ).  
B. The β-lactam based inhibitor cefoxitin (FOX) with piperacillin and ceftazidime.  	

C. The non-β-lactam inhibitor 10 with piperacillin and ceftazidime.  	
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Discussion.  
 
A cycle of structure-based design and testing led to several novel low micromolar inhibitors whose 
improved affinities could be analyzed on the basis of the X-ray structures subsequently determined 
for their complexes.  
The improved affinity is mirrored by the improved activity in cell culture: compound 10 inhibit β-
lactamase and do not up-regulate its expression in cell culture, as do classic β-lactam-based 
inhibitors. 
This antibiotic effect suggests that this series of inhibitors may be useful leads for further 
optimization. The X-ray crystal structures of compound 10 and 11 in complex with AmpC provide 
atomic resolution templates for future design efforts.  
X-ray crystallography. 
Scheme 1. Synthesis of 3-((4-chloroanilin)sulfonyl)thiophene-2-carboxylic acid derivatives	

	
a: Py dry, 50°C, N2. b: NaOH 2N, 80 °C, HCl dil.	
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Scheme 2. Synthesis of N-(4-Chloro-phenyl)-phthalamic acid derivative.	

	
a: DMF, DIEA, PyBOP. 60°C, N2. b: NaOH 2N, 80 °C, HCl dil.	
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